# Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

> **NCT00281840** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** docetaxel
- **PROCEDURE:** conventional surgery
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00281840
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2012-04
- **Final completion:** 2012-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2015-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00281840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00281840, "Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00281840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*